{"transactions":[{"id":4156633,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":171752,"kind":"organization","name":"EMBL Technology Fund II GmbH & Co. KG","position":1,"cik":"0001722607","reported_name":"EMBL Technology Fund II GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171753,"kind":"organization","name":"EMBL Ventures Verwaltungs GmbH","position":2,"cik":"0001722603","reported_name":"EMBL Ventures Verwaltungs GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171754,"kind":"person","name":"Adams Jan","position":3,"cik":"0001722536","reported_name":"Adams Jan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171755,"kind":"person","name":"Herr Stefan","position":4,"cik":"0001722440","reported_name":"Herr Stefan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171756,"kind":"person","name":"Muhlenbeck Frank","position":5,"cik":"0001646114","reported_name":"Muhlenbeck Frank","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T21:56:51.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":843613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held of record by EMBL Technology Fund II GmbH & Co. KG (\"EMBL\"). EMBL Ventures Verwaltungs GmbH is the general partner of EMBL. Dr. Jan Adams, Dr. Frank Muhlenbeck and Dr. Stefan Herr are the Managing Directors of EMBL Ventures Verwaltungs GmbH. By virtue of such relationships, EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr may be deemed to have voting and investment power with respect to the securities held by EMBL. Each of EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":247176},"source":{"system":"sec-edgar","filing":"0000899243-17-027103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1722603/000089924317027103/doc4.xml","form_type":"4"}},{"id":4156632,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":171752,"kind":"organization","name":"EMBL Technology Fund II GmbH & Co. KG","position":1,"cik":"0001722607","reported_name":"EMBL Technology Fund II GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171753,"kind":"organization","name":"EMBL Ventures Verwaltungs GmbH","position":2,"cik":"0001722603","reported_name":"EMBL Ventures Verwaltungs GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171754,"kind":"person","name":"Adams Jan","position":3,"cik":"0001722536","reported_name":"Adams Jan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171755,"kind":"person","name":"Herr Stefan","position":4,"cik":"0001722440","reported_name":"Herr Stefan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171756,"kind":"person","name":"Muhlenbeck Frank","position":5,"cik":"0001646114","reported_name":"Muhlenbeck Frank","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-11-20T21:56:51.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":207253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held of record by EMBL Technology Fund II GmbH & Co. KG (\"EMBL\"). EMBL Ventures Verwaltungs GmbH is the general partner of EMBL. Dr. Jan Adams, Dr. Frank Muhlenbeck and Dr. Stefan Herr are the Managing Directors of EMBL Ventures Verwaltungs GmbH. By virtue of such relationships, EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr may be deemed to have voting and investment power with respect to the securities held by EMBL. Each of EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":103278},"source":{"system":"sec-edgar","filing":"0000899243-17-027103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1722603/000089924317027103/doc4.xml","form_type":"4"}},{"id":4156631,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":171752,"kind":"organization","name":"EMBL Technology Fund II GmbH & Co. KG","position":1,"cik":"0001722607","reported_name":"EMBL Technology Fund II GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171753,"kind":"organization","name":"EMBL Ventures Verwaltungs GmbH","position":2,"cik":"0001722603","reported_name":"EMBL Ventures Verwaltungs GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171754,"kind":"person","name":"Adams Jan","position":3,"cik":"0001722536","reported_name":"Adams Jan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171755,"kind":"person","name":"Herr Stefan","position":4,"cik":"0001722440","reported_name":"Herr Stefan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171756,"kind":"person","name":"Muhlenbeck Frank","position":5,"cik":"0001646114","reported_name":"Muhlenbeck Frank","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T21:56:51.000Z","date":"2017-11-20","kind":"purchase","acquired":true,"shares":20000,"price":10,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held of record by EMBL Technology Fund II GmbH & Co. KG (\"EMBL\"). EMBL Ventures Verwaltungs GmbH is the general partner of EMBL. Dr. Jan Adams, Dr. Frank Muhlenbeck and Dr. Stefan Herr are the Managing Directors of EMBL Ventures Verwaltungs GmbH. By virtue of such relationships, EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr may be deemed to have voting and investment power with respect to the securities held by EMBL. Each of EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":370454,"source":{"system":"sec-edgar","filing":"0000899243-17-027103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722603/000089924317027103/doc4.xml","form_type":"4"}},{"id":4156630,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":171752,"kind":"organization","name":"EMBL Technology Fund II GmbH & Co. KG","position":1,"cik":"0001722607","reported_name":"EMBL Technology Fund II GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171753,"kind":"organization","name":"EMBL Ventures Verwaltungs GmbH","position":2,"cik":"0001722603","reported_name":"EMBL Ventures Verwaltungs GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171754,"kind":"person","name":"Adams Jan","position":3,"cik":"0001722536","reported_name":"Adams Jan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171755,"kind":"person","name":"Herr Stefan","position":4,"cik":"0001722440","reported_name":"Herr Stefan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171756,"kind":"person","name":"Muhlenbeck Frank","position":5,"cik":"0001646114","reported_name":"Muhlenbeck Frank","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T21:56:51.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":247176,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held of record by EMBL Technology Fund II GmbH & Co. KG (\"EMBL\"). EMBL Ventures Verwaltungs GmbH is the general partner of EMBL. Dr. Jan Adams, Dr. Frank Muhlenbeck and Dr. Stefan Herr are the Managing Directors of EMBL Ventures Verwaltungs GmbH. By virtue of such relationships, EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr may be deemed to have voting and investment power with respect to the securities held by EMBL. Each of EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":350454,"source":{"system":"sec-edgar","filing":"0000899243-17-027103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722603/000089924317027103/doc4.xml","form_type":"4"}},{"id":4156629,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":171752,"kind":"organization","name":"EMBL Technology Fund II GmbH & Co. KG","position":1,"cik":"0001722607","reported_name":"EMBL Technology Fund II GmbH & Co. KG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171753,"kind":"organization","name":"EMBL Ventures Verwaltungs GmbH","position":2,"cik":"0001722603","reported_name":"EMBL Ventures Verwaltungs GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171754,"kind":"person","name":"Adams Jan","position":3,"cik":"0001722536","reported_name":"Adams Jan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171755,"kind":"person","name":"Herr Stefan","position":4,"cik":"0001722440","reported_name":"Herr Stefan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171756,"kind":"person","name":"Muhlenbeck Frank","position":5,"cik":"0001646114","reported_name":"Muhlenbeck Frank","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T21:56:51.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":103278,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held of record by EMBL Technology Fund II GmbH & Co. KG (\"EMBL\"). EMBL Ventures Verwaltungs GmbH is the general partner of EMBL. Dr. Jan Adams, Dr. Frank Muhlenbeck and Dr. Stefan Herr are the Managing Directors of EMBL Ventures Verwaltungs GmbH. By virtue of such relationships, EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr may be deemed to have voting and investment power with respect to the securities held by EMBL. Each of EMBL Ventures Verwaltungs GmbH, Dr. Adams, Dr. Frank Muhlenbeck and Dr. Herr disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":103278,"source":{"system":"sec-edgar","filing":"0000899243-17-027103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722603/000089924317027103/doc4.xml","form_type":"4"}}]}